Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614454 · ClinicalTrials.gov registry record · Phase 2
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
A Phase 2 study of Neuromyelitis Optica, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT04614454 is a Phase 2 study of Neuromyelitis Optica that has completed, run by Massachusetts General Hospital. The registered enrollment target is 46 participants, below the 508-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04614454, a Phase 2 study of Neuromyelitis Optica, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to determine whether self-administered, at-home use of a transcutaneous electrical nerve stimulating device is an effective, acceptable and feasible method of relief from neuropathic pain among patients with Neuromyelitis optica spectrum disorder (NMOSD).
Conditions Studied
Interventions
- DEVICE High Frequency Impulse Therapy
- DEVICE High Frequency Impulse Therapy - Sham
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614454
The ClinicalTrials.gov registry entry for NCT04614454 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 508-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (91% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuromyelitis Optica appearing as the primary indexed condition, and to 2 interventions - of which High Frequency Impulse Therapy is the first listed.
NCT04614454 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04614454 about?
NCT04614454 is a clinical study titled "High Frequency Impulse Therapy for Neuropathic Pain in NMOSD". The aim of this study is to determine whether self-administered, at-home use of a transcutaneous electrical nerve stimulating device is an effective, acceptable and feasible method of relief from neuropathic pain among patients with Neuromyelitis optica spectrum disorder (NMOSD).
What is the current status of trial NCT04614454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2021-06-07. Estimated completion is 2025-01-15.
What conditions does trial NCT04614454 study?
This clinical trial studies the following conditions: Neuromyelitis Optica.
What interventions are being tested in trial NCT04614454?
The interventions under investigation include: High Frequency Impulse Therapy (DEVICE), High Frequency Impulse Therapy - Sham (DEVICE).
Who is sponsoring clinical trial NCT04614454?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04614454 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromyelitis Optica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
RECRUITING
-
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
RECRUITING · NA
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
ACTIVE NOT RECRUITING
-
Biobank For MS And Other Demyelinating Diseases
ACTIVE NOT RECRUITING
-
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
COMPLETED · Phase 4
-
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.